ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
8.40
+0.15 (1.82%)
At close: Aug 27, 2026, 4:00 PM EDT
8.41
+0.01 (0.12%)
After-hours: Aug 27, 2026, 7:59 PM EDT
ImmunityBio Stock Forecast
Stock Price Forecast
According to 4 analysts polled by S&P Global, ImmunityBio stock has a consensus rating of "Strong Buy" and an average price target of $12.75. The average 1-year stock price forecast is 51.79% higher than the current stock price, while the lowest is $12 (+42.86%) and the highest is $15 (+78.57%).
Price Target: $12.75 (+51.79%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for ImmunityBio stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 2 | 2 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 4 | 3 | 3 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Buy Maintains $12 | Buy | Maintains | $12 | +42.86% | Aug 5, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $15 | Buy | Reiterates | $15 | +78.57% | Aug 4, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $12 | Buy | Reiterates | $12 | +42.86% | Jun 1, 2026 |
Financial Forecast
Revenue This Year
225.73M
from 113.29M
Increased by 99.26%
Revenue Next Year
441.47M
from 225.73M
Increased by 95.57%
EPS This Year
-0.92
from -0.38
EPS Next Year
-0.13
from -0.92
EPS and Forward PE are based on non-GAAP adjusted numbers.